Drug intelligence / Profile preview

fecal microbiota transplant (Nanfang Hospital, Southern Medical University)

Development stage: Preclinical
Lead developer: Seres Therapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Fecal microbiota transplant (FMT) is an experimental biologic therapy being evaluated by investigators at Nanfang Hospital, Southern Medical University, for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease (GI-aGVHD). The treatment is administered as capsules containing live microorganisms (fecal microbiota) derived from healthy donors. The therapeutic goal is to restore gut microbial diversity in patients who have undergone allogeneic hematopoietic stem cell transplantation and developed GI-aGVHD. The mechanism involves modulating the patient's gut microbiome to reduce dysbiosis and repopulate beneficial commensal bacteria, such as butyrate-producing species, which are believed to have an immunomodulatory effect that can alleviate the pathogenesis of GVHD.

Other names: FMT capsule (Nanfang Hospital)fecal microbiota transplant-Nanfang Hospital, Southern Medical University-graft versus host disease (acute gastrointestinal)

Beyond the preview

Go deeper on fecal microbiota transplant (Nanfang Hospital, Southern Medical University).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fecal microbiota transplant (Nanfang Hospital, Southern Medical University).

Explore the full profile